Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Neuropharmacology. 2021 Dec 15;205:108925. doi: 10.1016/j.neuropharm.2021.108925

Fig. 1. A limited access oxycodone TBC-DID paradigm produces naloxone-precipitated withdrawal without the development preference.

Fig. 1.

A) The schematic shows the experimental timeline. B) An increasing oxycodone concentration did not impact the % preference for the treated bottle in mice subject to a six-day TBC-DID paradigm. C) The daily oxycodone dose (mg/kg) consumed increased as a function of oxycodone in a session-dependent manner. D) An increasing oxycodone concentration caused a dose-dependent increase in the number of naloxone-precipitated jumps. E) The number of naloxone-precipitated withdrawal jumps was positively correlated with the average daily dose (mg/kg) of oxycodone consumed during the TBC-DID sessions. Data are expressed as mean ± S.E.M. (n = 10 per group). “*” indicates high (1 mg/ml) concentration group vs. water (0 mg/ml) group where****p < 0.0001, **p < 0.01, *p < 0.05, “+”indicates high (1 mg/ml) vs. middle (0.5 mg/ml) concentration group, “X” indicates high (1 mg/ml) vs. low (0.1 mg/ml) concentration group, “#” indicates middle (0.5 mg/ml) concentration group vs. water (0 mg/ml) group, “$” indicates middle (0.5 mg/ml) vs. low (0.1 mg/ml) concentration group, and “^’indicates vs. Session 1 withing the same concentration group with the same symbol indications.